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ABSTRACT
BACKGROUND: The incidence of ovarian cancer ranks 8th in the world, with 295,414 cases and 184,799 death in 
2018. Management in ovarian cancer is surgery and chemotherapy. Some studies state that patients who underwent 
optimal cytoreduction surgery have better survival rates than suboptimal cytoreduction surgery. The pre-operative 
serum assessed in this study was Cancer Antigen-125 (CA-125), Fatty Acid Synthase (FASN), and Glucose 
Transporter (GLUT) to predict suboptimal cytoreduction in epithelial ovarian cancer (EOC).
AIM: We aimed to use FASN and GLUT1 as other biomarkers, besides CA-125, to predict suboptimal cytoreduction 
surgery in epithelial ovarian cancer. 
METHODS: This observational-analytic cross-sectional study included 109 women diagnosed with epithelial ovarian 
cancer (EOC) between 2017 and 2019, who had serum CA-125, FASN, and GLUT measured preoperatively and 
underwent cytoreductive surgery.
RESULTS: The results of the statistical analysis test in this study obtained p values at CA-125 (p = 0.0001), FASN 
(p = 0.017), and at GLUT (p = 0.013). While the cutoff point (COP) on CA-125 was 248.55, FASN was 0.445, and 
GLUT was 0.1980. The value of area under curve (AUC) obtained by the ROC method at CA-125 76.7%, FASN 
65.3%, and GLUT 63.8%. The combination of CA-125 and FASN shows AUC value 76.9%, the combination of 
CA-125 and GLUT shows AUC value 72.2%, and the combination of the three shows AUC value 75.2%.
CONCLUSION: The use of CA-125 as a predictor of cytoreduction surgery is still considered to be the best predictor 
compared to serum biomarkers in this study.
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Introduction
The number of new cases of ovarian cancer in 
2018 is 295,414. When compared to 2012, this number 
has increased by 56414 new cases [1], [2]. Likewise, 
the mortality rate in ovarian cancer has increased from 
152,000 in 2012 cases to 184,799 in 2018 [1], [2].
The standard of management of epithelial 
ovarian cancer is surgical staging in cases of early-stage 
(Stage 1) and cytoreduction surgery in cases of 
advanced stages (Stages 2, 3, and 4), which will be 
followed by adjuvant therapy of platinum-taksan class 
chemotherapy [3]. Cytoreduction surgery has aimed to 
remove all tumors. If this surgery leaves a tumor >1 cm 
called suboptimal cytoreduction surgery, if the remaining 
tumor <1 cm called optimal cytoreduction surgery [3], [4].
The success rate varies in cytoreduction 
surgery depending on many things, including the 
oncologist, completeness of the operating equipment in 
a hospital, degree of cancer based on the International 
Federation of Gynecology and Obstetrics (FIGO), the 
histopathological type of ovarian cancer, and body 
mass index [5], [6], [7]. A study assessed ovarian cancer 
patients, and 30% of samples underwent optimal 
cytoreduction surgery. In contrast, the others (70%) 
underwent suboptimal cytoreduction surgery. The 
high rate of suboptimal cytoreduction surgery makes 
management of ovarian cancer which has a low survival 
rate. The high rate of suboptimal cytoreduction surgery is 
due to the inability to predict the results of cytoreduction 
surgery well.
Cytoreduction surgery can be predicted in 
various ways; one of them is pre-operative assessment. 
The pre-operative assessment consists of clinical 
examinations, supporting examinations such as routine 
blood laboratory examinations, ultrasound examination 
(USG), X-rays, computed tomography scans (CT Scan), 
magnetic resonance imaging (MRI), positron emission 
tomography scan (PET Scan), and assessment of 
tumor markers [8], [9], [10], [11].
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Tumor markers that have been investigated 
as predictors of cytoreduction surgery are Cancer 
Antigen-125 (CA-125), human epididymis 4 protein 
(HE4), caspase 3, neutrophil to lymphocyte ratio (NLR), 
lymphocyte to monocyte ratio (LMR), vascular endothelial 
growth factor (VEGF) levels ) serum-peritoneum-VEGF 
load, and a combination of CA 125 with HE4, YKL 40, 
BCL 2, cathepsin L [12], [13], [14], [15], [16], [17].
Uncontrolled proliferation is one of the main 
characteristics of cancer. Proliferating cancer cells require 
much energy. The sources of energy comes from glucose 
and the glucose metabolism needs a transporter called 
GLUT (Glucose Transport). It was happened because of 
the increasing glycolysis process up to 30 times faster in 
cancer cells [18]. One of the sources of energy is Glucose. 
Increased glucose metabolism increases glucose transport 
(GLUT).  Previous studies had assessed that GLUT 
increased 20 times compared to healthy cells [19], [20], [21], 
[22], [23]. Glucose transporters typically found in ovarian 
cancer are GLUT1 (98.7%), GLUT3 (92.8%), and GLUT4 
(84.4%) [24]. GLUT1 is the essential transporter in the 
absorption of glucose in tumor cells. The increase of 
GLUT1 levels has a relationship in worsening survival 
rates in ovarian cancer patients [24], [25]. Various studies 
have been conducted further to analyze the role of GLUT 
as a cancer predictor. Patients with advanced tumors are 
considered to have excessive GLUT1 expression, which 
will result in the possibility of suboptimal cytoreduction 
surgery [26]. This reason has led researchers to make 
GLUT1 one of the tumor markers assessed in this study.
Besides requiring glucose, cancer cells also need 
fatty acids. In cancer cells, the fatty acids needed come from 
food consumed (exogenous) or from the metabolism of fatty 
acids in the body (lipogenesis de novo) [27]. The primary 
source of fatty acids is from food consumed or exogenous, 
but the cancer cells will increase the production of fatty acids 
in the body or de novo lipogenesis. The synthesis of these 
fatty acids requires the activation of several enzymes; one 
of them is fatty acid synthase (FASN). FASN contributes 
to the process of fatty acid oxidation and biogenesis in cell 
membranes, which can thus divide rapidly [28]. Studies 
conducted by Cai et al. found that an increase of FASN 
was associated with the degree of cancer and the stage of 
cancer [28]. In stage IV, ovarian cancer has a higher FASN 
94.1% compared to stage I ovarian cancer 1.25% [29], [30].
Due to the perceived strong relationship 
between FASN and GLUT1, the researchers will use 
FASN and GLUT1 as other biomarkers assessed 
in this study besides CA-125 to predict suboptimal 
cytoreduction surgery in epithelial ovarian cancer.
Methods
The design of this study was a prospective 
observational analytic with a cross-sectional study 
design. In this study, researchers will look for a 
relationship between the independent variables 
(risk factor) with the dependent variable (effect). The 
population in this study was patients with a diagnosis of 
suspected ovarian malignant tumors who would undergo 
cytoreduction surgery at RSUP Dr. Hasan Sadikin. The 
inclusion criteria in this study were all new patients 
with epithelial ovarian cancer, underwent cytoreduction 
surgery techniques, willing to follow the study after 
giving informed consent, and not suffering from chronic 
diseases or other tumors. A consecutive sampling made 
the selection of subjects of the population in the 2017–
2019 period in Dr. Hasan Sadikin Hospital Bandung.
Before surgery, the entire population in this study 
will take blood to assess serum biomarker levels. Serum 
examination by Enzyme-Linked Immunosorbent Assay 
technique was carried out at the Eyckman Laboratory, 
Faculty of Medicine, Padjadjaran University. In patients 
who were confirmed histopathologically, not epithelial 
ovarian cancer or stage I patients would be exclusion 
criteria in this study. In addition, if the histopathological 
preparations are damaged or cannot be assessed, did 
not undergo cytoreduction surgery, and did not willing to 
be sampled in the study will be excluded from this study.
Serum biomarkers CA-125, FASN, and GLUT 
are independent variables, and the dependent variable 
in this study is optimal and suboptimal cytoreduction 
surgery. All data will be assessed statistically using 
SPSS™ (24.0.0). If the data are normally distributed, 
it will use paired t-test analysis, whereas if it is not 
normally distributed, it will use Mann–Whitney analysis. 
As for categorical data, p-values will be analyzed using 
the Chi-Square test, and if the Chi-Square requirements 
are not met, we will use the Kolmogorov–Smirnov, and 
exact Fisher tests. The cut off point (COP) was made 
using receiver operating characteristic (ROC) curve 23 
analysis.
Results
There were 304 patients for the population 
in this study for the period 2017–2019. A total of 195 
patients did not meet the inclusion criteria, so there 
were 109 patients sampled in this study. There were 56 
patients underwent suboptimal cytoreduction surgery, 
while 53 others underwent optimal cytoreduction 
surgery (Table 1). The youngest sample is 17 years old, 
while the oldest is 75 years old (Table 1). There were 
28 (25.7%) samples with parity 0, 16 (14.7%) samples 
with parity 1, 23 (21.1%) samples with parity 2, and 42 
(38.5%) samples with parity> 3 (Table 1).
A total of 57 samples were patients with Stage 
III malignancy, 42 samples were patients with Stage II 
malignancy, and 10 samples were patients with Stage 
IV malignancy. The most histopathological types in this 
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study were the mucinous type with 38 patients (34.9%), 
the serous with 27 patients (24.8%), the endometrioid 
with 21 patients (19.3%), the clear cell with 16 patients 
(14.7%), and others with 7 patients (6.4%) (Table 1). There 
were no differences between the variables of age, parity, 
BMI (Body Mass Index), stage and histopathology with p 
values greater than 0.05 (Table 1). The stage variable has 
a p < 0.05 (p = 0.0001), so there is a difference between 
the suboptimal and optimal cytoreduction groups (Table 1).
Table 1: Background characteristics of the study population
Variable N=109 Group p value
Suboptimal 
cytoreduction
Optimal 
cytoreduction
n = 56 n = 53
Age (years) 0.269
Mean ± Std 47.48 ± 11.347 48.66 ± 9.648 46.24 ± 12.880
Median 47.00 47.00 47.00
Range (min-max) 17/00–75.00 26.00–64.00 17.00–75.00
Parity 0.261
0 28 (25.7%) 16 (28.6%) 12 (22.6%)
1 16 (14.7%) 6 (10.7%) 10 (18.9%)
2 23 (21.1%) 15 (26.8%) 8 (15.1%)
>3 42 (38.5%) 19 (33.9%) 23 (43.4%)
Body Mass Index 0.353
Mean ± Std 21.30 ± 3.907 20.96 ± 3.675 21.66 ± 4.143
Median 21.30 21.25 21.40
Ascites 0.089
Mean ± Std 1652.56 ±  
3664.119
1703.75 ±  
3393.296
1598.49 ±  
3962.289
Median 300.00 400.00 300.00
Stage 0.0001
II 42 (38.5%) 8 (14.3%) 34 (64.2%)
III 57 (52.3%) 38 (67.9%) 19 (35.8%)
IV 10 (9.2%) 10 (17.9%) 0 (0.0%)
Histopathology 0.559
Serous 27 (24.8%) 18 (32.1%) 9 (17.0%)
Mucinous 38 (34.9%) 12 (21.4%) 26 (49.1%)
Endometrioid 21 (19.3%) 14 (25.0%) 7 (13.2%)
Clear cell 16 (14.7%) 8 (14.3%) 8 (15.1%)
Others 7 (6.4%) 4 (7.1%) 3 (5.7%)
Serum CA-125 values in the suboptimal 
cytoreduction group (1157.62 ± 2105.195) were 
higher than those in the optimal cytoreduction group 
(237.52 ± 319.431), as well as the values on the FASN, 
GLUT, FASN + CA-125 combination, GLUT + CA-125 
combination, and the combination of GLUT + FASN + 
CA-125 have higher values in patients with suboptimal 
cytoreduction group than patients with optimal 
cytoreduction group (Table 2). Based on P-value 
analysis of CA-125 (p = 0.0001), FASN (p = 0.006), 
GLUT (p = 0.013), FASN + CA-125 combination 
(p = 0.0001), GLUT + CA-125 combination (p = 0.0001), 
and GLUT + FASN + CA-125 combination (p = 0.0001), 
p values in serum biomarkers have a value of less than 
0.05 which means that there are significant differences 
in the suboptimal and optimal cytoreduction group 
patient variables (Table 2).
The subsequent analysis is to analyze how the 
cutoff point for each biomarker. In Table 3 described the 
cutoff value for each serum biomarker. CA-125 has the 
cutoff point 248.55 (p = 0.0001) with a sensitivity value 
(73.2%), specificity (73.6%), and an accuracy value 
(73.3%) (Table 3). Whereas the FASN did not appear to 
have a sensitivity value (62.5%), specificity (60.4%), and 
an accuracy value (61.4%), which was better than CA-125 
(Table 3). The cut off value for FASN serum biomarkers is 
0.445, which means if the patient has a serum value > 0.445.
has 65.3% (AUC value) is likely to undergo suboptimal 
cytoreduction surgery. It seems that GLUT also does not 
provide better results than CA-125 and FASN. Patients 
who have a GLUT serum biomarker > 0.1980 have 63.8% 
(AUC value) chance of having suboptimal cytoreduction 
surgery. The sensitivity value of this biomarker is 75%, and 
its specificity is 56.6% (Table 3).
Table 2: Comparison between CA-125, FASN, and GLS 
serums level in the suboptimal sitoreduction and optimal 
sitoreduction groups
Variable Group p value
Suboptimal 
cytoreduction 
Optimal 
cytoreduction 
n = 56 n = 53
CA-125 0.0001
Mean ± Std 1157.62 ± 2105.195 237.52 ± 319.431
Median 600.00 120.30
Range (min-max) 4.29–9934.00 5.10–1941.90
FASN 0.006
Mean ± Std 0.58 ± 0.271 0.46 ± 0.288
Median 0.50 0.37
Range (min-max) 0.11–1.59 0.03–1.19
GLUT 0.013**
Mean ± Std 0.41 ± 0.337 0.33 ± 0.298
Median 0.28 0.19
Range (min-max) 0.11–1.47 0.04–1.42
Combination FASN + CA-125 0.0001**
Mean ± Std 1.02 ± 0.581 0.55 ± 0.314
Median 0.93 0.49
Range (min-max) 0.21–3.18 0.03–1.58
Combination GLUT + CA-125 0.0001
> 0.3793 38 (67.9%) 18 (34.0%)
< 0.3793 18 (32.1%) 35 (66.0%)
Combination GLUT+FASN+CA-125 0.0001**
Mean ± Std 1.18 ± 1.212 0.54 ± 0.483
Median 0.79 0.35
Range (min-max) 0.16–5.88 0.08–1.86
In addition to using biomarker values as a 
single predictor, this study is also using a combination 
of biomarker values as predictors of suboptimal 
cytoreduction surgery. This combination value uses 
CA-125 as a categorical value where if the patient has 
a value > 248.55 is 2, and if the patient has a value < 
248.55 is 1. The formula for three combination biomarker 
used two variables CA-125 and FASN as the categorical 
value based on each cut off point, where the value of 
CA-125 was > 248.55 = 2 and < 248.55 = 1 or FASN level 
was > 0.445 = 2 and <0.445 =1, while for the combination 
of CA-125 + FASN and CA-125 + GLUT used CA-125 
as categorical value. This categorical value will then be 
multiplied by the value of each pair of combinations.
The combination value of CA-125 and FASN 
has a cutoff value of 0.69 (p = 0.0001) with a sensitivity 
value of 71.4%, specificity of 71.7%, and an accuracy 
value of 71.6% (Table 3). While the combination 
of CA-125 and GLUT has a cutoff point of 0.3793 
(p = 0.0001) with a sensitivity of 67.9%, specificity 
66%, and an accuracy value of 67% (Table 3). The 
combination of CA-125 + FASN + GLUT with a cutoff 
value of 0.5150 has sensitivity 71.4%, a specificity 
71.7%, and an accuracy value of 71.6% (Table 3).
Furthermore, each biomarker will be analyzed 
using ROC curve 23 analysis to illustrate in what direction 
the curve will move from the 50% line. The CA-125 is 
depicted in Figure 1. The curves in the ROC analysis 
move away from the 50% line and approach 100%, with 
a value of 76.7% (p = 0.000), which can illustrate that 
the CA-125 can predict 84 patients correctly from a total 
of 109 patient (Figure 1). Figure 2 illustrates FASN as 
a predictor of cytoreduction surgery with an area under 
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Table 3: Sensitivity and specificity of predictor cytoreduction scoring of epithelial ovarian cancer
Variable Cutoff Sensitivity % Specificity % AC % PPV % NPV % p Value
CA-125 248.55 73.2 73.6 73.3 74.5 72.2 0.0001
FASN 0.445 62.5 60.4 61.4 62.5 60.4 0.017
GLUT 0.1980 75 56.6 66.1 64.6 68.2 0.001
Combination CA-125 and FASN 0.69 71.4 71.7 71.6 72.7 70.4 0.0001
Combination CA-125 and GLUT 0.3793 67.9 66 67 71.7 66 0.0001
Combination CA-125, FASN, and GLUT 0.5150 71.4 71.7 71.6 72.7 70.4 0.0001
AC: Accuracy classification, PPV: Positive predictive value, NPV: Negative predictive value
curve (AUC) value of 65.3% (p = 0.006). This AUC FASN 
value was described as being able to predict 71 patients 
correctly from a total of 109 patients. Not much different 
from GLUT can only predict 70 patients correctly from 
109 patients (AUC value 63.8% p = 0.0013) (Figure 3). 
AUC value of a combination of FASN + GLUT + CA-125 
is 75.2% (p = 0.000), this value can correctly predict 82 
patients out of 109 patients (Figure 4).
Figure 1: ROC curve showing the value of CA-125 with cytoreduction. 
Area under curve value was 76.7% CI 67.8%-85.6% (p = 0.000), 
implicating that CA-125 can predict cytoreduction correctly in 84 
patients out of a total of 109 patients
Discussion
Cytoreduction surgery plays an essential role 
in the management of epithelial ovarian cancer. Tumor 
residues are considered to be a prognostic factor of the 
survival rate of patients. The standard management 
of epithelial ovarian cancer management is surgical 
therapy and followed by platinum therapy and taksan 
for advanced stage [31]. Based on the GOG Guideline, 
the main goal for cytoreduction procedures is to take 
all parts of the tumor or leave the tumor part with size 
<1 cm (optimal cytoreduction) [32]. Based on research 
conducted by Bacalbasa in 2014, he collected 338 
patients who were willing to be the subjects in his study. 
He found that 242 patients who underwent optimal 
cytoreduction had an increase in survival compared to 
patients who underwent suboptimal cytoreduction [33].
Figure 2: ROC curve showing the value of FASN with cytoreduction. 
Area under curve value was 65.3% CI 54.8%-75.8% (p = 0.006), 
implicating that FASN can predict cytoreduction correctly in 71 
patients out of a total of 109 patients
Figure 3: ROC curve showing the value of GLUT with cytoreduction. 
Area under curve value was 63.8% CI 53.2% sampai 74.4% 
(p = 0.0013), implicating that GLUT can predict cytoreduction 
correctly in 70 patients out of a total of 109 patients
A - Basic Sciences Pathology
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An appropriate predictor tool is needed 
to assess whether the patient can do optimal 
cytoreduction or not. Several methods have been used 
to predict the results of cytoreduction surgery such 
as physical examination, ultrasound examination, CT 
scan, and laboratory examination. However, it seems 
that the predictor tool still has many shortcomings. 
Tumor markers that have been investigated as 
predictors of cytoreduction surgery are CA-125, human 
epididymis 4 protein (HE4), Caspase 3, neutrophil 
to lymphocyte ratio (NLR), lymphocyte to monocyte 
ratio (LMR), vascular endothelial growth factor 
(VEGF) levels serum-peritoneum-VEGF load, and a 
combination of CA 125 with HE4, YKL 40, BCL 2, and 
cathepsin L [12], [13], [14], [15], [16], [17]. Therefore, 
in this study researchers are trying to find alternative 
examinations that are expected to be other predictors 
than CA-125, namely, FASN and GLUT.
Figure 4: ROC curve showing the value of combination FASN and 
CA-125 with cytoreduction. Area under curve value was 76.9% CI 
68.1%-85.8% (p = 0.0000), implicating that FASN and CA-125 can 
predict cytoreduction correctly in 84 patients out of a total of 109 
patients
CA-125 or commonly referred to as CA-125 
is the most studied serum biomarker as a predictor 
of cytoreduction surgery. Vorgias et al. in their study 
entitled “Can the pre-operative Ca-125 predict optimal 
levels of cytoreduction in patients with advanced ovarian 
carcinoma? A single institution cohort study” examining 
426 patients with stage III/IV ovarian cancer stated 
that CA-125 is a good predictor for predicting optimal 
cytoreduction. Furthermore, Vorgias said that the cutoff 
point of CA-125 is 500 IU/mL with the sensitivity 78.5%, 
the specificity 89.6%, positive predictive value 84.2%, 
negative predictive value 85.4%, and the accuracy 
rate 85% [34]. Based on the recommendations of The 
Society of Gynecologic Oncology and the American 
Society of Clinical Oncology Clinical Practice Guideline 
that every patient who has a low likelihood of optimal 
cytoreduction, then it is better to receive NACT therapy 
first [35]. Even the study from Canada stated that the 
reduction in CA-125 during chemotherapy was related 
to the success rate of cytoreduction surgery [36].
In this study was found that there were 
significant differences in CA-125 as a predictor of 
cytoreduction surgery (p = 0.0001). The cutoff point 
of CA-125 as a predictor was 248.55 U/mL, with a 
sensitivity 73.2%, a specificity 73.6%, and an accuracy 
rate 73.3% (Table 3). Figure 1 shows ROC curve 
of CA-125 with cytoreduction with AUC value that 
was 76.7% CI 67.8%-85.6% (p = 0.000), implicating 
that CA-125 can predict cytoreduction correctly in 84 
patients out of a total of 109 patients.
In normal biological systems, levels of CA-125 
or Mucin 16 (MUC-16) are expressed in several epithelial 
layers of organs such as the mouth, esophagus, lungs, 
breast, large intestine, ovary, and cervix. CA-125 has 
the function of hydration and lubrication to maintain 
the mucosal layer of epithelial cells and protect the cell 
surface from pathogen attack [37]. Regulatory errors in 
CA-125 play a role in cancer pathogenesis [13], [37]. In 
ovarian cancer, MUC16 will interact with NK cells through 
the Siglec receptor-9 and cause immunosuppression. 
This MUC16 will interact with galectin 1 and 3 in 
cancer cells, which will cause an increase in cancer 
progressivity [37].
Various evidence has been found about 
changes in several branches of metabolism that 
support the transformation of malignancy. Changes 
in metabolism that occurs in cancer are associated 
with activation of proto-oncogenes and inactivation of 
tumor suppressor genes. Various oncogenic signaling 
pathways are needed in tumor cell metabolism to support 
cell growth and resistance. Various cellular metabolic 
changes to support the three basic need of cells that 
are dividing; the formation of adenosine triphosphate 
(ATP) increase macromolecular biosynthesis and 
monitor redox conditions. Cancer cells require changes 
in all significant macromolecular metabolic pathways: 
Carbohydrates, proteins, lipids, and nucleic acids [27].
FASN and GLUT play an essential role in the 
metabolic changes that exist in cancer cells. FASN 
plays a role in lipogenesis de novo, a mechanism 
of synthesis of fatty acids in the body. The rapid 
proliferation of cancer cells requires large amounts of 
fatty acids [38]. The lipogenesis de novo process will 
produce saturated fatty acids and monounsaturated 
fatty acids. These types of fatty acids make cancer 
cells survive from oxidative stress, which will cause cell 
death. Besides, fatty acids in large quantities can also 
reduce the absorption of drugs by cancer cells which 
will cause resistance to therapy [39].
Increased synthesis of fatty acids in tumor 
cells will increase the activation of several enzymes in 
the lipogenic pathway. Increased FASN activity found 
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in early oncogenesis, which would correlate with the 
pathogenesis of cancer. Therefore, an increase in 
FASN expression can indicate a more aggressive type 
of cancer cell [28].
Until now, there have been no studies using 
serum FASN as a predictor of suboptimal surgery 
in ovarian cancer. Stefanie et al. said in their study 
that benign ovarian tumors have low FASN numbers 
when compared to malignant ovarian tumors. In FASN 
staining, high-grade serous carcinoma has a higher 
score compared to low-grade serous carcinoma [29].
There was a significant difference in FASN as 
a predictor of cytoreduction surgery (p = 0.006). The 
cutoff point of FASN as a predictor was 0.445, with a 
sensitivity 62.5%, a specificity 60.4%, and an accuracy 
rate 61.4% (Table 3). Figure 2 shows ROC curve of 
FASN with cytoreduction with AUC value was 65.3% CI 
54.8%-75.8% (p = 0.006), implicating that FASN can 
predict cytoreduction correctly in 71 patients out of a 
total of 109 patients.
The next biomarker serum is GLUT, one of the 
proteins that play a role in transporting glucose. Glucose is 
a source of fuel for almost all body cells, including cancer 
cells. Glucose will go through processes glycolysis, the 
Krebs cycle, and oxidative phosphorylation to supply 
energy in the form of ATP. Malignant cells will tend to 
metabolize through the process of glycolysis, and it 
will require faster glucose absorption [18]. The glucose 
demand will increase GLUT expression.
Based on Table 2, GLUT has a significant 
difference as a predictor of cytoreduction surgery 
(p = 0.013). The use of GLUT as a predictor of 
cytoreduction surgery resulted in a sensitivity of 75% 
and specificity 56.6%, with a cutoff point of 0.1980 
(Table 2). Figure 2 shows the ROC curve of GLUT 
with cytoreduction with AUC value that was 63.8% CI 
53.2–74.4% (p = 0.0013), implicating that GLUT can 
predict cytoreduction correctly in 70 patients out of a 
total of 109 patients.
The combination of CA-125 + FASN 
produces a cutoff point of 0.69 with CA-125 as a 
categorical group (1; ≦ 248.55, 2> 248.55). The use 
of this combination has a sensitivity rate of 71.4%, a 
specificity of 71.7%, and an accuracy rate of 71.6% 
(p = 0.0001). While the combination of CA-125 + 
GLUT produces a cutoff point of 0.3793 with CA-125 
as a categorical group (1; ≦ 248.55, 2> 248.55). 
The use of this combination has a sensitivity rate of 
67.9%, a specificity of 66%, and an accuracy value of 
67% (p = 0.0001).
The combination of the three namely CA-125 
+ FASN + GLUT can correctly predict 82 patients out 
of 109 patients (Figure 6) using CA-125 (1; ≦ 248.55, 
2> 248.55) and FASN (1; ≦ 0.445, 2 > 0.445) as a 
categorical group. All three have a cutoff point of 0.5150 
(table 3.) with a sensitivity value of 71.4%, specificity of 
71.7%, and an accuracy value of 71.6%.
Figure 5: ROC curve showing the value of combination GLUT and 
CA-125 with cytoreduction. Area under curve value was 72.2% CI 
62.3%-82.1% (p = 0.000), implicating that GLUT and CA-125 can 
predict cytoreduction correctly in 79 patients out of a total of 109 patients
Figure 6: ROC curve showing the value of combination CA-125, FASN, 
and GLUT with cytoreduction. Area under curve value was 75.2% CI 
65.9–84.5%. (p = 0.000), implicating that CA-125, FASN, and GLUT can 
predict cytoreduction correctly in 82 patients out of a total of 109 patients
Conclusion
Although the use of CA-125 has not been 
proven to be specific as a predictor of cytoreduction 
surgery, it seems that GLS and FASN are no better 
than the use of CA-125. Neither the combination nor 
the value of the biomarker singly does not have better 
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results than the use of CA-125. It is hoped that this 
research can provide an overview of other biomarkers 
for their use as predictors of cytoreduction surgery.
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